| Autor: |
Magdalena Samborska, Małgorzata Barańska, Jacek Wachowiak, Jolanta Skalska-Sadowska, Sheanda Thambyrajah, Małgorzata Czogała, Walentyna Balwierz, Sylwia Kołtan, Katarzyna Peszyńska-Żelazny, Mariusz Wysocki, Tomasz Ociepa, Tomasz Urasiński, Grażyna Wróbel, Jadwiga Węcławek-Tompol, Bogna Ukielska, Alicja Chybicka, Anna Kitszel, Maryna Krawczuk-Rybak, Anna Szmydki-Baran, Iwona Malinowska, Michał Matysiak, Agnieszka Mizia-Malarz, Renata Tomaszewska, Tomasz Szczepański, Agnieszka Chodała-Grzywacz, Grażyna Karolczyk, Lucyna Maciejka-Kembłowska, Ninela Irga-Jaworska, Wanda Badowska, Michał Dopierała, Paweł Kurzawa, Katarzyna Derwich |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 12 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2022.935373 |
| Popis: |
IntroductionMyeloid sarcoma (MS) is an extramedullary malignant tumor composed of immature myeloid cells. It occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). MS may coincide with disease diagnosis or precede bone marrow involvement by months or even years; it can also represent the extramedullary manifestation of a relapse (1, 2).AimThe aim of this study is to describe clinical characteristics of children diagnosed with MS in Poland as well as to analyze diagnostic methods, treatment, and outcomes including overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS). The study also attempted to identify factors determining treatment outcomes.PatientsThe study group comprised 43 patients (F=18, M=25) aged 0-18 years (median age, 10.0 years; mean age, 8.8 years) diagnosed with MS based on tumor biopsy and immunohistochemistry or identification of underlying bone marrow disease and extramedullary tumor according to imaging findings.MethodsThe clinical data and diagnostic and therapeutic methods used in the study group were analyzed. A statistical analysis of the treatment outcomes was conducted with STATISTICA v. 13 (StatSoft, Inc., Tulsa, OK, USA) and analysis of survival curves was conducted with MedCalc 11.5.1 (MedCalc Software, Ostend, Belgium). Statistical significance was considered at p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
